about
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancerBRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status.Mutations of PIK3CA in gastric adenocarcinomaRaf family kinases: old dogs have learned new tricksAutocrine PDGFR signaling promotes mammary cancer metastasisMolecular origins of cancer: Molecular basis of colorectal cancerMutant proteins as cancer-specific biomarkersMicrosatellite instability in colorectal cancerRoles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceGlucose deprivation contributes to the development of KRAS pathway mutations in tumor cellsDetection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodologyBRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targetsRecognition and binding of mismatch repair proteins at an oncogenic hot spotPolymorphisms of the BRAF gene predispose males to malignant melanomaPredictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of OptionsNew trends in molecular and cellular biomarker discovery for colorectal cancerNovel therapeutic agents in the treatment of metastatic colorectal cancerBRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapiesAmeloblastoma: A Review of Recent Molecular Pathogenetic DiscoveriesMolecular phenotypes of colorectal cancer and potential clinical applicationsSimilar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistanceOvarian serous carcinoma: recent concepts on its origin and carcinogenesisSerrated lesions of the colorectum: review and recommendations from an expert panelAre KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinomaMolecular alterations and biomarkers in colorectal cancerColorectal Cancer Biomarkers: Where Are We Now?Molecular profile of colorectal cancer in Indonesia: is there another pathway?Raf activation is regulated by tyrosine 510 phosphorylation in DrosophilaClinical implications of BRAF mutation test in colorectal cancer.Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.Opportunities for immunotherapy in microsatellite instable colorectal cancerBiomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and othersMechanisms of resistance to anti-EGFR therapy in colorectal cancerMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerObesity and colorectal cancer: molecular features of adipose tissueConcordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastasesRegulation of Raf through phosphorylation and N terminus-C terminus interaction
P2860
Q21142734-C52F4508-76C8-4E9B-AE23-1A9B600386C9Q21245742-3C42B869-61DE-477E-AFD3-C3E1F0832EA2Q21261219-9843C72D-FBF1-4151-B7B1-03E8C7863F28Q24316181-F856B44A-F328-4B10-8CB4-0B18CB4289E6Q24545375-6B39507E-466C-4BAE-BAD8-DBFA96FAAC8EQ24617331-B033C85D-CD18-4D8C-8479-335ACAED21E4Q24625180-2396C53E-A870-4A06-A742-DE510CBAAEEEQ24627393-EA9CB8BD-740E-4D33-9497-2B33C7773C3AQ24645668-ADC3A614-9121-46BC-AAD5-A146DE54045DQ24648994-A61E847E-5523-4910-B696-426489837BBDQ24681980-AFB075CF-FB58-4C60-A397-7B4250D562A6Q24685106-4C9FAE88-0F42-4341-AAD2-9F8E3C644A08Q24805338-6FBDB6C3-B5A6-4AAD-B811-F72BD588C2B4Q24806439-C94A8575-D33E-4687-9225-C2B544E23D0FQ26738655-6ECBA60A-29F3-459F-8E50-43B0BACA5AFAQ26739049-4A787C1C-C0C8-4AA7-A43D-5111EB70EBC2Q26769932-25BF31A0-B1A0-4F26-BE37-36174D2F7A8CQ26772276-C0A9D4ED-1025-444F-AD36-858C95512137Q26781648-7B9EBD7E-1D4B-4C7C-9F60-8DA9E5443A90Q26785725-C0B7D7D2-5125-4E4F-AAAC-72E798C1FBA4Q26795609-1312F54B-5385-43B1-AC80-4062A9C85779Q26822545-4AF8A5A1-E2ED-4FD3-A580-E51FCCBF8BB6Q26827208-324D80EA-D7CE-4C0A-89B9-F631D04A492BQ26828992-9A2742B6-60EF-4BED-896B-BCAC7FBC413FQ26853261-6EB2BE4A-2530-4426-A891-521D1959EF96Q26862317-B4E5CEE3-F960-4A54-8242-35CDF2237196Q27003134-0E39D910-BE4A-4E62-87AC-5D18FF39A904Q27004659-AD19553C-3059-4C1E-A08D-2389E5C3425EQ27333187-B9A4B574-06B2-45C8-877A-770C7710D679Q27692120-7238F022-B220-40E9-B735-4CA8F8848C61Q27824825-DAE8A5F7-A236-4D2E-9CF3-3347E1D636EEQ27852431-97E16180-D169-47ED-AC8F-CAF3F4E4EB4CQ27853224-0420D017-464A-480E-96E4-EDA0864CE55DQ28066110-88BABD7B-2E62-4FF7-91DC-846CD0894A57Q28072468-AA65AA90-80BD-4A8F-8638-2039D0FCF9B2Q28074073-4DD69A9F-E469-452C-BAEF-4033946AD9B9Q28076490-F783B184-22E2-42B6-AD85-876FF568DADEQ28079556-413C000E-F241-4255-AF1F-5994F8B6281BQ28088489-2CA071A3-410A-45C9-9955-F0165BEFC16FQ28187593-AE207B92-0200-4C63-AA0C-B0F58C1E13FC
P2860
description
article publiƩ dans la revue scientifique Nature
@fr
scientific article published in Nature
@en
wetenschappelijk artikel
@nl
Š½Š°ŃŠŗŠ¾Š²Š° ŃŃŠ°ŃŃŃ, Š¾ŠæŃŠ±Š»ŃŠŗŠ¾Š²Š°Š½Š° Š² Nature Š² ŃŠµŃŠæŠ½Ń 2002
@uk
name
RAF/RAS oncogenes and mismatch-repair status
@en
RAF/RAS oncogenes and mismatch-repair status
@nl
type
label
RAF/RAS oncogenes and mismatch-repair status
@en
RAF/RAS oncogenes and mismatch-repair status
@nl
prefLabel
RAF/RAS oncogenes and mismatch-repair status
@en
RAF/RAS oncogenes and mismatch-repair status
@nl
P2093
P2860
P50
P356
P1433
P1476
RAF/RAS oncogenes and mismatch-repair status
@en
P2093
Christoph Lengauer
Harith Rajagopalan
Victor E. Velculescu
P2860
P2888
P304
P356
10.1038/418934A
P407
P577
2002-08-01T00:00:00Z
P6179
1042017236